CYTR CytRx Corporation

0.32
-0.01  -3%
Previous Close 0.33
Open 0.33
Price To Book 0.56
Market Cap 10,764,000
Shares 33,637,501
Volume 133,587
Short Ratio 1.96
Av. Daily Volume 196,573

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma. Rolling NDA to be filed 4Q 2017.
Aldoxorubicin with doxorubicin
Soft tissue sarcomas refractory cancer
Phase 2 trial completed.
Aldoxorubicin
Cancer - unresectable glioblastoma
Phase 1b dosing initiated February 2018.
Aldoxorubicin
Squamous Cell Carcinoma
Phase 2/3 interim analysis 1H 2020 with data due 1H 2021.
Arimoclomol
sporadic Inclusion Body Myositis (sIBM)
Phase 1b dosing initiated February 2019.
Aldoxorubicin
Refractory colorectal cancer (CRC)

Latest News

  1. Nasdaq delists shares of FTD, Insys, others
  2. CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
  3. CytRx Corporation to Commence Trading on OTCQB Venture Market
  4. CytRx: 1Q Earnings Snapshot
  5. CytRx Corporation Reports First Quarter 2019 Financial Results
  6. CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
  7. CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
  8. CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
  9. CytRx Corporation Reports 2018 Financial Results
  10. CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
  11. CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor
  12. CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
  13. CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
  14. CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
  15. CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
  16. CytRx Corporation to Present at the 11th Annual LD Micro Main Event
  17. Report: Exploring Fundamental Drivers Behind Graphic Packaging Holding, QEP Resources, Inogen, CytRx, Voyager Therapeutics, and Daily Journal Corp. (S.C.) — New Horizons, Emerging Trends, and Upcoming Developments
  18. Edited Transcript of CYTR earnings conference call or presentation 2-Nov-18 3:00pm GMT
  19. Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
  20. Bet on Rising P/E Investing With These 5 Top-Ranked Stocks